FundedIQ
Health Care

Elasmogen

Elasmogen is developing soloMERs: fully humanized, next generation, single chain therapeutics for auto-inflammatory diseases, ophthalmology, oncology and intracellular delivery. soloMERs are proprietary humanized clinical candidates derived from VNARS (variable new-antigen receptors) which exist naturally in sharks as high affinity binding domains. With a different ancestral origin from antibodies this example of 400 million year old convergent evolution places VNARs outside of the complex patent landscape that describes and protects antibody drug discovery and has produced the smallest (9% of the size of an antibody) and most robust naturally occurring binding domain. Elasmogen is unique in its capacity to isolate and develop soloMERs, with a multi-layered IP position covering the platform, products and process including an exclusive license to over 20 patents granted in the US, Europe and other territories together with the entire know-how and VNAR pipeline/product output from the Scottish Biologics Facility, University of Aberdeen.

www.elasmogen.com Aberdeen, United Kingdom 11-50 employees
Total raised
$9.9M
Rounds
1
Latest
Venture - Series Unknown
May 2022

Elasmogen is developing soloMERs: fully humanized, next generation, single chain therapeutics for auto-inflammatory diseases, ophthalmology, oncology and intracellular delivery. soloMERs are proprietary humanized clinical candidates derived from VNARS (variable new-antigen receptors) which exist naturally in sharks as high affinity binding domains. With a different ancestral origin from antibodies this example of 400 million year old convergent evolution places VNARs outside of the complex patent landscape that describes and protects antibody drug discovery and has produced the smallest (9% of the size of an antibody) and most robust naturally occurring binding domain. Elasmogen is unique in its capacity to isolate and develop soloMERs, with a multi-layered IP position covering the platform, products and process including an exclusive license to over 20 patents granted in the US, Europe and other territories together with the entire know-how and VNAR pipeline/product output from the Scottish Biologics Facility, University of Aberdeen.

Elasmogen has raised $9.9M across 1 round. Its most recent round was a Venture - Series Unknown of $9.9M in May 2022. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
May 18, 2022
Venture - Series Unknown
$9.9M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Elasmogen is featured in

Similar companies

Neubond

Neubond develops wearable devices for stroke mobility rehabilitation. These devices provide autonomous assistance and therapy during daily activities, integrating rehabilitation into the patient's daily life regardless of their motor capabilities. Neubond's solutions are designed to be intuitive and effective, aiming to improve the quality of life for individuals undergoing rehabilitation.

Seed $2.0M
Silveray

Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market.

Series A $6.6M
Nebu-Flow

Nebu-Flow is a manufacturer of the next generation of inhaled drugs for patients with respiratory disorders. The company is a developer of the technology control of the droplet size for deep lung deposition by enabling injection-free systemic drug delivery through inhalation routes for cardiovascular and central nerve system disorders. Nebu-Flow is committed to minimizing the environmental impact of activities whilst continuing to create a user-friendly and high-performing Nebuliser.

Series Unknown $2.7M
iFast Diagnostics

iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

Seed $3.9M
Creo Medical

Innovative medical gadgets are created by Creo Medical Limited, situated in Chepstow, South Wales. With a variety of clinically useful tools, Creo Medical's distinctive bipolar radiofrequency and microwave energy platform enables precise tissue effects to be achieved. The first tool conducts flexible endoscopic dissection of gastrointestinal tract tissue anomalies. With the first set of tools, a flexible endoscope will be used to address a variety of issues in gastroenterology. The CROMA platform and product line will expand into new therapeutic spheres like laparoscopic surgery and the management of certain malignant lesions.

Series Unknown $7.4M
TympaHealth

TympaHealth has developed the world's first ear and hearing health assessment system. The Tympa system empowers non-specialists to perform high definition digital otoscopy, microsuction wax removal and a hearing screening, all in a single 30 minute appointment. Users can also upload patient images and video to the secure cloud, where they can be reviewed by ENT specialists anywhere in the world.

Series Unknown $2.7M
NEX Health Intelligence

NEX Health Intelligence (NEX) is a health-tech business that develops AI-powered software for hospitals to detect, track, and prevent illnesses, including drug-resistant epidemics.

Pre-Seed $1.2M
Infex Therapeutics

Infex Therapeutics acquire, develop and license drugs to treat pandemic infections.

Series Unknown $5.8M
Asterix Health

Asterix Health is the workforce solution for modern healthcare.

Pre-Seed $2.9M
Gloucester Rugby

Gloucester Rugby is a professional English rugby union club that gives up to date with all the information for men and women teams. Its local importance extends well beyond the city. It is a high-performing team that is recognised internationally and an average of 15,000 supporters.

Series Unknown $430k
PlaqueTec

PlaqueTec is pioneering the development of biomarker-based strategies to transform the prevention, diagnosis, and treatment of Coronary Artery Disease, the leading cause of death worldwide. As with any successful startup, PlaqueTec has a strong leadership team with a unified vision for continued growth, and a commitment to changing the current standard of care in the diagnosis, prevention, and treatment of CAD. They work closely with cardiologists, academic scientists, and biopharmaceutical companies around the world to advance understanding of CAD and the inflammatory processes underlying the progression of this common and dangerous disease, and to accelerate the testing of existing and new therapeutic agents for CAD.

Series Unknown $5.0M
Medpal AI

Medpal is an AI-powered personal health consultant that revolutionizes healthcare management. This platform uses artificial intelligence and machine learning to provide tailored health recommendations, monitor health data, and offer medical guidance. By making healthcare knowledge accessible, Medpal empowers people to make informed decisions about their well-being, irrespective of their location or socioeconomic status leading to more equitable health outcomes for all.

Series Unknown $4.1M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.